459 results about "Umbilical cord" patented technology

The invention relates to a medicine, a medicine composition and application of the medicine and the medicine composition in treatment of liver fibrosis. The medicine and the medicine composition comprise an umbilical cord mesenchymal stem cell membrane; the umbilical cord mesenchymal stem cell membrane is prepared by the following steps: coating the surface of a temperature-sensitive culture dish with a matrix; adding the cell suspension of the umbilical cord mesenchymal stem cells into a temperature-sensitive culture dish for culturing; the temperature is reduced, the umbilical cord mesenchymal stem cells and the extracellular matrix secreted by the umbilical cord mesenchymal stem cells are separated in a lamellar mode, and the umbilical cord mesenchymal stem cell membrane is obtained. The medicine and the medicine composition provided by the invention can effectively relieve liver fibrosis.

The invention discloses a cord blood-derived regulatory T cell amplification culture medium and a use method thereof, and relates to the field of animal cell culture and immune cell therapy, the culture medium is a serum-free culture medium, the culture medium is composed of a basic culture medium, a serum substitute combination, a combination of four cell factors, an immunosuppressor, an apparent stabilizer and an antioxidant, and all the components play a role synergistically; according to the use method, cell amplification is realized through a collaborative process of staged environmental regulation and targeted activation. According to the method, the problems of exogenous pollution and batch difference caused by dependence of a serum-containing system on cord blood-derived regulatory T cell amplification in the prior art are solved, the defect that a serum-free scheme is difficult to consider the amplification efficiency and the function stability at the same time is overcome, the cell amplification quality and the clinical application safety are guaranteed, and the method is suitable for large-scale clinical transformation requirements.

The invention discloses a therapeutic nano-vesicle preparation rich in mitochondrial functional protein, a preparation method of the therapeutic nano-vesicle preparation and application of the therapeutic nano-vesicle preparation in treatment of radioactive skin injury. The preparation method comprises the following steps: culturing, amplifying and cleaning umbilical cord mesenchymal stem cells, dispersing the umbilical cord mesenchymal stem cells in a suspension, mechanically extruding the umbilical cord mesenchymal stem cells into a crude solution through a multistage aperture polycarbonate membrane, and centrifuging, concentrating and purifying the crude solution to obtain the preparation. The preparation has the remarkable advantages that local administration can be realized, inflammation can be quickly inhibited, oxidative stress is reduced, and a repair pathway is activated, so that the preparation is suitable for treating acute radioactive skin injury; the preparation method is easy to standardize and scale, high in stability and convenient for emergency storage and delivery, and avoids the defects of cell therapy; a plurality of targets such as immune inflammation, oxidative stress and the like can be synergistically regulated, the biological effect of hUMSCs is simulated and partially replaced, and the limitation caused by the cell survival rate and the microenvironment dependency is avoided; the key function of hUMSCs is covered in function, and the clinical feasibility, safety and emergency suitability of the application level are higher.

The invention discloses a ready-to-use activated human umbilical cord mesenchymal stem cell as well as a preparation method and application thereof. The preparation method comprises the following steps: carrying out passage on P0-generation cells for three times to obtain P3-generation cells; cryopreserving P3 generation cells, and establishing a cell seed bank; resuscitating the cells in the seed bank for three times of passage to obtain P6-generation cells; and carrying out activation culture on the P6-generation cells, and resuspending the activated P6-generation cells in a cell protective agent to obtain the human umbilical cord mesenchymal stem cell original suspension. The invention also discloses an umbilical cord mesenchymal stem cell cryopreservation preparation. The cryopreservation preparation is obtained by mixing the human umbilical cord mesenchymal stem cell original suspension with a cryopreservation protective agent, sub-packaging and cryopreserving. Experiments prove that the human umbilical cord mesenchymal stem cell cryopreserved preparation prepared by the invention can be stored for a long time, is convenient to store, transport and use clinically, can complete effectiveness and safety index detection within the shelf life, and has the same activity as a fresh preparation.

The invention discloses application of a stem cell exosome in treating depression-like behaviors caused by high-altitude hypoxia, and belongs to the technical field of biomedicine. The stem cell exosome is an exosome derived from human umbilical cord mesenchymal stem cells, and is used for drugs for preventing and / or treating depression-like behaviors caused by high-altitude hypoxia. The exosome can effectively improve depression-like core behavior symptoms caused by high-altitude hypoxia by regulating a brain-intestinal axis; the method starts from remodeling intestinal flora so as to influence the intracerebral metabolite spectrum, and finally plays a role in neuroprotection by regulating and controlling a 5-HT6 / cAMP-PKA key signal channel. In addition, the combination of the hUC-MSC-exo and probiotics shows synergistic interaction potential, and a potential treatment strategy which is novel in mechanism, remarkable in effect and high in safety is provided for the field.

The invention relates to the technical field of cell drug preparation process optimization, in particular to an umbilical cord stem cell drug preparation parameter optimization method utilizing machine learning, which comprises the following steps: preprocessing to generate a control input time sequence and an observation output time sequence, and forming a process instruction library; constructing an intervening state space model based on the two types of time sequences, and assimilating the intervening state space model; defining multiple targets and constraints, compiling a process, simulating on the model, determining a feasible region by combining statistical calibration and formalized verification, and generating a feasibility judgment function; and carrying out microparameterization on the process in the feasible region and optimizing under constraints, carrying out rolling solution according to a preset prediction window in the model prediction control framework, outputting an optimal process flow and a monitoring threshold value, and executing record backflow updating. According to the method, the replicability, the compliance and the cross-batch robustness of the process are enhanced.

The present invention relates to an incubation system for liquid-based incubation of prematurely born infants, comprising: —an inner chamber forming an amniotic basin comprising amniotic fluid, said basin being configured for holding said infant and being made from a flexible material configured for expanding said inner chamber volume in correspondence with the growth of said infant; —an outer chamber enclosing said inner chamber and comprising a temperature regulation fluid, —a fetal connection port, arranged for connecting with the umbilical cord of said infant, said umbilical cord providing a port in said inner chamber to said infant for providing dialyzation and nutrition compounds to said infant via said umbilical cord; —a fetal control unit, connected to said fetal connection port for control of said dialyzation and control of said provided nutrition by monitoring and controlling one or more of a pressure, flow and temperature thereof; an amniotic fluid circulation unit, arranged for connecting with an inlet / outlet port of said inner chamber and comprising a pump for circulating said amniotic fluid from said inner chamber and through a purification system located outside said inner chamber; and —a temperature regulation fluid control unit, arranged for connecting with an inlet / outlet port of said outer chamber and comprising a pump for circulating said temperature regulation fluid from said outer chamber and through a heat exchanger system located outside said inner chamber.

The invention relates to the technical field of rhinitis spray preparation, in particular to a method for preparing allergic rhinitis spray from umbilical cord mesenchymal stem cell exosomes, which comprises the following steps: 1, umbilical cord treatment; 2, culturing umbilical cord mesenchymal stem cells; 3, preparing an umbilical cord mesenchymal stem cell exosome; and 4, preparing the rhinitis spray. The rhinitis spray prepared by the method disclosed by the invention is simpler and more convenient to use. The exosome, the platelet growth factor and other substances in the rhinitis spray well solve the core problems of single curative effect, large side effect, low compliance and the like in the traditional rhinitis treatment, and through the induction and repair functions of the stem cell exosome and the bactericidal ability of the antibacterial peptide, the nasal cavity environment is improved, the anaphylactic reaction is reduced, the nasal mucosa is repaired, and the rhinitis treatment effect is improved. The allergic rhinitis is expected to be fundamentally treated.

The invention provides an extraction method of umbilical cord mesenchymal stem cell exosomes. The extraction method comprises the following steps: S1, collecting umbilical cord mesenchymal stem cell culture supernatant; s2, centrifuging the culture supernatant under a centrifugal force of 250-350 g, and collecting the supernatant to obtain a first mixed solution; s3, centrifuging the first mixed solution under a centrifugal force of 1500-2500 g, and collecting a supernatant to obtain a second mixed solution; s4, centrifuging the second mixed solution under a centrifugal force of 9000-11000 g, and collecting a supernatant to obtain a third mixed solution; and S5, filtering the third mixed solution, centrifuging under the centrifugal force of 90000-110000 g, collecting the precipitate, adding a PBS buffer solution, centrifuging under the centrifugal force of 90000-110000 g, and collecting the precipitate to obtain the umbilical cord mesenchymal stem cell exosome. The umbilical cord mesenchymal stem cell exosome with the purity up to 99% is extracted from the culture supernatant through twice low-speed centrifugation and three times of high-speed centrifugation.

The invention relates to the technical field of biology, in particular to application of active polypeptide in maintaining dryness of umbilical cord mesenchymal stem cells. The active polypeptide disclosed by the invention is PNC-27, and the amino acid sequence of the PNC-27 is as shown in SEQ ID NO: 1. Experiments find that the PCN-27 polypeptide can effectively promote proliferation of the umbilical cord mesenchymal stem cells by regulating expression of periodic proteins Cyclin-D1 and CDK1, and can also effectively maintain dryness of the umbilical cord mesenchymal stem cells by promoting expression of dry gene Oct-4 protein in the umbilical cord mesenchymal stem cells. Experiments fully prove that the PCN-27 polypeptide can effectively maintain the dryness of the umbilical cord mesenchymal stem cells and stimulate the potential application value of the umbilical cord mesenchymal stem cells in the fields of cell culture, biomedicine and the like.

The present application relates to the technical field of biological medicine, and particularly relates to a stem cell culture method for promoting wound healing and application thereof. The stem cell culture method for promoting wound healing comprises the following steps: step one, providing umbilical cord-derived mesenchymal stem cells; step two, adding luteolin and baicalin as culture medium additives in a serum-supplemented culture medium, wherein the concentration of luteolin is 1-10 micromoles / L, and the concentration of baicalin is 1-10 micromoles / L; step three, inoculating the mesenchymal stem cells into the culture medium containing the additives for culture, and the culture condition is 34-40 DEG C, 4-6% CO2, and the culture time is 48-96 hours; step four, harvesting the cultured mesenchymal stem cells to obtain stem cells for promoting wound healing. The culture method can promote the stem cells to secrete various growth factors, significantly improve the secretion of PGE2 and VEGF-C growth factors, and make the wound healing rate of the stem cell treatment group reach 96%, which has a significant effect on treating diabetic foot ulcers.

The invention relates to a bioactivity-related characteristic marker of umbilical cord mesenchymal stem cell-derived small extracellular vesicles and application of the bioactivity-related characteristic marker. The bioactivity-related characteristic marker of the umbilical cord mesenchymal stem cell-derived small extracellular vesicles comprises one or a combination of more than two of a PSMB3 protein, an SAA4 protein, a VPS33B protein and an AKR7A2 protein. The invention provides a screening method of the characteristic markers, and particularly, the biological activity of the human umbilical cord mesenchymal stem cell source extracellular vesicles can be effectively judged by detecting the characteristic markers or the combination of the characteristic markers of the umbilical cord mesenchymal stem cell source extracellular vesicles. An evaluation means and an important reference are provided for product quality control, clinical transformation and the like based on the umbilical cord mesenchymal stem cell-derived small extracellular vesicles.

The present invention relates to the technical field of stem cell detection, and particularly relates to a determination method for purity and population doubling time of human umbilical cord mesenchymal stem cells (hUC-MSCs). The cultured hUC-MSCs are mixed with the buffer solution to obtain cell suspension; the cell suspension is mixed and incubated with a fluorescein-labeled antibody to obtain an incubated substance; and the incubated substance is centrifuged, and the precipitate obtained is cleaned and then mixed with the buffer solution to obtain a substance to be tested. The present invention analyzes cell surface markers and cell cycles by using a flow cytometer and monoclonal antibodies labeled with different fluoresceins of hUC-MSCs as well as PI staining, and further defines a determination method for purity and population doubling time of hUC-MSCs.

The invention discloses application of CD146 + umbilical cord mesenchymal stem cell subpopulation in preparation of drugs for preventing and treating immune thrombocytopenia and a product, and relates to the technical field of biology. The invention provides an application of a CD146 + mesenchymal stem cell subset in preparation of a medicine for treating or preventing immune thrombocytopenia. The CD146 < + > mesenchymal stem cell subpopulation can increase the number of platelets of ITP patients, regulate the CD4 < + > / CD8 < + > ratio of the ITP patients and remarkably reduce the MDSC proportion, so that the in-vivo immune state is changed.

The invention belongs to the technical field of hair cosmetics, and relates to a biological active matter composition, freeze-dried powder of the biological active matter composition, a preparation method of the freeze-dried powder, hair-fixing and scalp-loss-preventing essence of a biological plant double-active composition formula and a preparation method of the hair-fixing and scalp-loss-preventing essence. The essence is composed of a double-activity omics formula system of a biological active matter composition and a plant active matter composition. The biological active matter composition comprises an umbilical cord active extract, composite polypeptide and yeast powder, and freeze-dried powder is prepared by adopting a micro-capsule wrapping freeze-drying locking technology. The plant active matter composition comprises a cacumen biotae extract, a nasturtium officinale extract, a swertia bimaculata extract and a plant oil control agent, and is prepared into a microcrystal liquid solvent by adopting an efficient redissolution and infiltration promotion technology. Compared with the prior art, by adopting a double-activity formula system of the biological active matter composition and the plant active matter composition, the hair papilla cell viability can be remarkably improved, the comprehensive functions of moisturizing, nourishing, oil controlling, dandruff removing and breakage preventing are enhanced, and the hair loss preventing effect is better.

The invention discloses a PDRN-loaded umbilical cord mesenchymal stem cell source nano-vesicle and a preparation method thereof, and belongs to the technical field of biological medicines. The preparation method provided by the invention comprises the following steps: mixing an umbilical cord mesenchymal stem cell suspension with a PDRN solution, and carrying out freeze thawing treatment; incubating the mixed solution subjected to freeze thawing treatment; extruding the incubated mixed solution for multiple times by using a filter membrane; and collecting the extruded product, and separating and purifying to obtain the PDRN-loaded umbilical cord mesenchymal stem cell source nano-vesicle. According to the preparation method disclosed by the invention, the encapsulation efficiency of PDRN is remarkably improved, meanwhile, secondary damage of a traditional post-loading technology to a preformed vesicle structure is avoided, the membrane integrity and biological activity of a final product are better maintained, the yield is high, and the preparation process is rapid; the introduction of exogenous impurities is avoided from the source, and the high purity and biological safety of the obtained nano-vesicle component are ensured.

The invention relates to the technical field of bioengineering, in particular to a preparation method of a probiotic and exosome preparation applied to immunoregulation. The probiotics and the umbilical cord stem cell exosome are combined for use, the immune regulation effect is enhanced from multiple targets and multiple ways, the immune function of the body is improved, the exosome carries a specific molecular marker and acts on immune cells in a targeted mode, precise immune regulation is achieved, and the preparation is in an oral form and convenient to use; the exosome is extracted from umbilical cord stem cells, has no pathogenicity and immunogenicity, and is low in adverse reaction risk after being used for a long time, and the prepared combined preparation can be used for treating and preventing various immune-related diseases, and also can be used for daily conditioning of people with low immunity and improving the body resistance; meanwhile, the combined preparation adopts micro-capsule embedding, so that the probiotics can be effectively protected from gastric acid and bile erosion, the survival rate and colonization efficiency of the probiotics in intestinal tracts are improved, the immunoregulation effect is further enhanced, and the combined preparation is convenient to store and transport and has a good application prospect.

The invention discloses a preparation method of a three-dimensional umbilical cord mesenchymal stem cell exosome and application of the three-dimensional umbilical cord mesenchymal stem cell exosome in the fields of medicines and medical beauty. The preparation method comprises the step of amplifying umbilical cord mesenchymal stem cells (UC-MSCs) by adopting a three-dimensional culture system. Experiments show that IGF-1, EGF, VEGF, TGF-beta, PDGF, FGF and the like in the exosome subjected to three-dimensional culture are beneficial to skin repair and oxidation resistance, and the content of cell active factors for promoting collagen secretion is remarkably increased. The umbilical cord mesenchymal stem cell exosome significantly improves the fibroblast proliferation activity, and UV-induced skin fibroblast damage model construction and function verification experiments also prove that the exosome can promote the HA level recovery of damaged skin fibroblasts. The invention provides an efficient and safe biological material for tissue repair.

The invention provides an immortalized NK cell line SZ093 derived from healthy human umbilical cord blood as well as a preparation method and application of the immortalized NK cell line SZ093. The immortalized NK cell line SZ093 derived from the healthy human umbilical cord blood is preserved in Guangdong Microbial Culture Collection Center on September 26, 2025, and the preservation number is GDMCC No: 67036. The immortalized NK cell line SZ093 derived from the healthy human umbilical cord blood, provided by the invention, can still keep good multiplication capacity and high survival rate in a long-time (more than one year) culture process, and has high killing capacity on tumor cells.

The invention discloses a culture method for hypoxia culture of umbilical cord mesenchymal stem cells, which comprises the following steps: hypoxia pre-adaptive culture: inoculating umbilical cord mesenchymal stem cells in a culture medium containing bFGF (basic fibroblast growth factor), glutathione, astragalus polysaccharide and salidroside, and transferring the umbilical cord mesenchymal stem cells into a 5% O2 environment after the umbilical cord mesenchymal stem cells are preliminarily adhered to the wall in a normal oxygen environment; performing low-oxygen enrichment culture: replacing a second culture medium containing astragalus polysaccharide, salidroside, D-ribose, sodium pyruvate and D-glucose, and promoting efficient cell proliferation under 2% O2; performing function strengthening culture: adding tanshinone IIA and GSK-269962A, inducing cells to secrete VEGF under 1% O2, and maintaining high dryness. According to the method, through the synergistic effect of the three-stage gradient oxygen concentration and the specific serum-free culture medium, the cell proliferation multiple is remarkably increased, the total apoptosis rate is reduced, VEGF secretion is promoted, the multidirectional differentiation potential is reserved, the culture method is standardized in operation, the serum-free culture medium is definite in component, and a high-quality stem cell culture scheme is provided for the field of regenerative medicine.

The invention relates to the technical field of cosmetics, and discloses an umbilical cord blood moisturizing essence composition, an umbilical cord blood moisturizing essence as well as a preparation method and application of the umbilical cord blood moisturizing essence. The composition contains a hydrolyzed placenta extract, placenta protein, an umbilical cord extract, a guava fruit extract, a radix gentianae extract, decapeptide-4, nonapeptide-1, a lactobacillus fermentation product and a yeast fermentation product filtrate. The umbilical cord blood moisturizing essence prepared from the composition has multiple effects of moisturizing, repairing and resisting aging, and is mild, safe, excellent in stability and high in active ingredient retention rate.

The present invention relates to the field of image analysis technology, specifically to a method and system for monitoring the preparation process of umbilical cord mesenchymal stem cells, comprising the following steps: based on the umbilical cord mesenchymal stem cell image, image size standardization, noise removal, cell region cropping, grayscale value comparison to remove grayscale value regions below a set threshold, and filtering to eliminate background noise, remove noise points, and extract cell edge information to generate a denoised cell image. In the present invention, by introducing a residual network and convolution operation, cell morphological changes are accurately captured, providing more accurate proliferation state analysis, cell boundary extraction and cycle classification improvements, effectively avoiding the misjudgment of cell state in traditional methods, and deep learning training optimizes image segmentation, making cell cycle division more accurate, ensuring the efficiency and accuracy of the entire monitoring process, and ensuring the standardization and efficiency of the stem cell preparation process.

The invention relates to the technical field of biomedical information, in particular to an umbilical cord mesenchymal stem cell donor matching database construction method based on HLA (human leukocyte antigen) typing, which comprises the following steps of: recording and storing data of a donor in a database to finish initial construction of the database; regularly rechecking the donor data record stored in the database, and updating the state identifier of the donor data record when the rechecked data is changed by a preset degree; and receiving a matching request containing the human leukocyte antigen typing data of the target patient and the target disease type, performing donor screening in the database by using a preset comprehensive matching degree model based on the matching request, and optimizing parameters of the comprehensive matching degree model through a machine learning model based on the matching record and the clinical curative effect data corresponding to the matching record. According to the method, the accuracy and effectiveness of umbilical cord mesenchymal stem cell treatment are improved, and meanwhile, the system has continuous self-evolution ability.

The invention discloses an umbilical cord mesenchymal stem cell serum-free culture medium, which is composed of a basic culture medium and additive components, and the additive components comprise, by final concentration, 5-20 [mu] g / mL of astragalus polysaccharide, 0.5-2.0 [mu] g / mL of salidroside, 0.1-0.5 [mu] g / mL of tanshinone IIA, 0.1-0.3 mg / mL of sodium pyruvate, 5-15 mM of D-ribose, 3-6 mg / mL of recombinant human albumin, and 5-10 [mu] g / mL of recombinant transferrin; the invention also discloses a method for culturing umbilical cord mesenchymal stem cells under the hypoxia condition by using the serum-free culture medium. The method comprises the steps of cell inoculation, culture under the hypoxia condition, subculture, cell passage and the like. The astragalus polysaccharide, the salidroside, the tanshinone IIA, the sodium pyruvate, the recombinant human albumin and the recombinant transferrin are added into the serum-free culture medium, so that nutrition supply and function maintenance of cells under a low-oxygen condition are guaranteed, the proliferation rate and the differentiation capacity of the cultured cells are improved, the apoptosis rate of the cells is reduced, and the survival rate of the cells is increased. Wide application prospects are realized in the fields of cell culture, regenerative medicine and the like.

The invention relates to the field of cell engineering and gene engineering, in particular to a method for enhancing the multiplication capacity of umbilical cord mesenchymal stem cells and application. The expression or activity of the STN1 gene in the umbilical cord mesenchymal stem cells is reduced through an accelerant, and the umbilical cord mesenchymal stem cells with enhanced multiplication capacity are obtained. By knocking down the hUC-MSCs of STN1, the proliferation speed of the hUC-MSCs is higher, DNA replication is more active, the clone formation ability is higher, and the aging proportion of the hUC-MSCs can be remarkably reduced.

The invention discloses an application of silibinin in enhancing the immunomodulatory function of stem cells, and relates to the technical field of biological medicines. The silybin is applied to the composition for enhancing the immunoregulation function of the stem cells, the composition comprises the silybin and umbilical cord-derived mesenchymal stem cells, and the immunoregulation function of UC-MSCs is enhanced by adjusting the interaction of ICOS / ICOSL axes based on the combined action of the silybin and the umbilical cord-derived mesenchymal stem cells. The silybin disclosed by the invention is competitively combined with the ICOS, so that the interaction of the ICOS / ICOSL is blocked, and the immune regulation function of the umbilical cord-derived mesenchymal stem cells is remarkably enhanced; therefore, the UC-MSCs show a stronger immunosuppression effect in both in-vitro and in-vivo experiments; silybin not only acts on an ICOS / ICOSL axis, but also inhibits secretion of inflammatory factors through a PI3K / AKT signal channel, so that a multi-mechanism synergistic treatment effect is achieved.

In one embodiment, a method for performing meningeal repair includes closing an open meningeal defect with a human umbilical cord meningeal patch.

This invention discloses recombinant umbilical cord mesenchymal stem cells related to pentamericin 3 in the field of genetic engineering, their preparation method, and applications. The technical problem this invention aims to solve is how to provide a cell product capable of treating bone regeneration insufficiency. To solve this technical problem, this invention provides recombinant umbilical cord mesenchymal stem cells, which are prepared according to a method comprising the following steps: upregulating or enhancing or increasing the content and / or activity of pentamericin 3 or the expression of the gene encoding said protein in the umbilical cord mesenchymal stem cells, thereby obtaining the recombinant umbilical cord mesenchymal stem cells. The recombinant umbilical cord mesenchymal stem cells provided by this invention can be used to treat diseases related to bone regeneration insufficiency.

The application belongs to the technical field of cell culture, and particularly relates to umbilical cord blood-derived endothelial cell culture additives, an endothelial cell culture method and application. The umbilical cord blood-derived endothelial cell culture additives comprise activated platelet-rich plasma and at least one of miR-132 and miR-193b-3p high expression and miR-155 low expression exosomes. The application further provides an endothelial cell culture medium comprising the umbilical cord blood-derived endothelial cell culture additives, and the culture medium can significantly improve the growth state of HUVEC cells and effectively reduce or even avoid the vacuolization phenomenon in the culture process.

The invention discloses a culture method for inducing high expression of umbilical cord mesenchymal stem cells (LRP1) and application, and belongs to the technical field of biological medicines. The technical problem to be solved is to provide a standardized culture method for directionally inducing a specific functional phenotype cell population, so that efficient and accurate induction of LRP1 high-expression UCMSCs is realized, and clinical adaptation is met. According to the key point of the technical scheme, the culture method for inducing the LRP1 high-expression umbilical cord mesenchymal stem cells comprises the following steps: inoculating umbilical cord mesenchymal stem cells into a culture dish at the inoculation density of 5.5 * 10 < 3 > / cm < 2 > to 3.6 * 10 < 4 > / cm < 2 >, and culturing for 24-72 hours by using a special mesenchymal stem cell culture medium without adding a supplement, so that the acquisition efficiency of the LRP1 high-expression UCMSCs is improved, and the yield of the LRP1 high-expression UCMSCs is increased. Antibody labeling and flow sorting are not needed, so that the operation steps are simplified, and the complexity and cost of the culture process are reduced.